Prostate CancerNCT00578240
Molecular Studies and Clinical Correlations in Human Prostatic Disease
An observational study of Prostate Cancer, run by Memorial Sloan Kettering Cancer Center at 1 site in United States.
Trial summary
The Genitourinary Oncology/Urology Services at Memorial Sloan-Kettering Cancer Center (MSKCC) participates in research for the control, treatment, and cure of cancer. The purpose of this study is to collect normal and cancerous tissues, in addition to blood, and other body fluid samples from men with prostate cancer… Read more about this study
- Who is it for?
- Any age, men only
- Conditions the study is for
- Prostate Cancer
- How many people
- 5,290 participants
- Where
- 1 siteUnited States
- Study dates
- Apr 1990to Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Men only
- No healthy volunteers
- Child, Adult, Older adult
Study population: All patients meeting the eligibility criteria and receiving or seeking prostate cancer treatment in the Genitourinary Oncology/Urology Services will be approached by a consenting professional at a suitable point in their clinical course prior to biospecimen collection.
Who may be able to join
- Men with prostate conditions representing the following disease states:
- No Cancer Diagnosis
- Clinically Localized Disease
- Rising PSA
- Clinical Metastases: Noncastrate
- Clinical Metastases: Castrate (Testosterone ≤ 50 ng/ml)
- Signed informed consent
Who cannot join
- -Patients without any prostate related problems.
Trial locations and contacts
1 site in 1 country.
United States1 site
Memorial Sloan Kettering Cancer Center
New York, New York, 10065
About this study
The Genitourinary Oncology/Urology Services at Memorial Sloan-Kettering Cancer Center (MSKCC) participates in research for the control, treatment, and cure of cancer. The purpose of this study is to collect normal and cancerous tissues, in addition to blood, and other body fluid samples from men with prostate cancer or prostatic disease. These samples may be stored for future use or used immediately by researchers who study prostate cancer and try to find better ways to diagnose, prevent, and treat it. We will look for genetic changes and protein markers on these cells. We hope to learn more about what makes some people get prostate cancer, why some cancers are more aggressive than others, and why some cancers respond to or resist different treatments. We may also try to grow the tumor cells in the lab. We may find a new treatment for prostate cancer based on this research.
Read the detailed description
The therapeutics program for advanced prostate cancer is based on the hypothesis that the factors contributing to and associated with progression change as the disease evolves. To categorize these changes we now consider the disease as a series of states. 1 The states represent points where an intervention might be considered to prevent cancer from developing, to eliminate established disease, or to delay progression. The states also represent clinically significant milestones that can be used to assess treatment effects.
- Conditions
- Prostate Cancer
- Keywords
- benign, Rising PSA, Clinical Metastases, 90-040
- Medical subject headings
- Prostatic Neoplasms
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Dec 2007 (estimated)
- Study startApr 1990
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Prostate CancerStudies of the same condition, open and under way.
- More trials run by Memorial Sloan Kettering Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Other
- Enrolment
- 5,290 participants (actual)
Sponsor and investigators
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Sponsor type
- University, hospital or other
- Collaborators
- Rockefeller University, Flinders Medical Centre, University of Southern California, Gen-Probe, Incorporated, Genentech, Inc., General Electric, Purdue University, Biocept, Inc., Duke University, Ikonysis, Array Genomics, Cold Spring Harbor Laboratory, Nodality, Epic Sciences, Rutgers Cancer Institute of New Jersey, Dana-Farber Cancer Institute, Johns Hopkins University, M.D. Anderson Cancer Center, Oregon Health and Science University, University of California, San Francisco, University of Chicago, University of Michigan, University of Washington, University of Wisconsin, Madison, Fred Hutchinson Cancer Center, Broad Institute of MIT and Harvard, Weill Medical College of Cornell University, Institute of Cancer Research, United Kingdom, Vitatex Inc., Serametrix Corporation, Promega Corporation, Creatv Microtech, Inc., Viatar LLC, Massachusetts Institute of Technology, Advanced Cell Diagnostics, ApoCell, Inc., Beckman Coulter GmbH, Bioview, Inc., Clearbridge BioMedics Pte Ltd., Singapore, Cynvenio Biosystems, Exosome Diagnostics, Inc., Fluxion Biosciences, Foundation Medicine, Universitätsklinikum Hamburg-Eppendorf, Brooklyn ImmunoTherapeutics, LLC, Ohio State University, Palo Alto Research Center, Rarecells, Silicon Biosystems, The Scripps Research Institute, University of Minnesota, Janssen Diagnostics, LLC, University of Regensburg, Innocrin Pharmaceuticals Inc.
- Responsible party
- Sponsor
- Investigators
- Susan Slovin, MD, Principal investigator, Memorial Sloan Kettering Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00578240
- Sponsor's protocol ID
- 90-040
- Status last verified
- Mar 2026
- First submitted
- 19 Dec 2007
- Last updated
- 9 Mar 2026
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Molecular Studies and Clinical Correlations in Human Prostatic Disease
- ClinicalTrials.gov ID
- NCT00578240
- Acronym / sponsor ID
- 90-040
- Conditions
- Prostate Cancer
- Keywords
- benign, Rising PSA, Clinical Metastases, 90-040
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 5,290 participants (actual)
- Lead sponsor
- Memorial Sloan Kettering Cancer CenterUniversity, hospital or other
- Collaborators
- Rockefeller University, Flinders Medical Centre, University of Southern California, Gen-Probe, Incorporated, Genentech, Inc., General Electric, Purdue University, Biocept, Inc., Duke University, Ikonysis, Array Genomics, Cold Spring Harbor Laboratory, Nodality, Epic Sciences, Rutgers Cancer Institute of New Jersey, Dana-Farber Cancer Institute, Johns Hopkins University, M.D. Anderson Cancer Center, Oregon Health and Science University, University of California, San Francisco, University of Chicago, University of Michigan, University of Washington, University of Wisconsin, Madison, Fred Hutchinson Cancer Center, Broad Institute of MIT and Harvard, Weill Medical College of Cornell University, Institute of Cancer Research, United Kingdom, Vitatex Inc., Serametrix Corporation, Promega Corporation, Creatv Microtech, Inc., Viatar LLC, Massachusetts Institute of Technology, Advanced Cell Diagnostics, ApoCell, Inc., Beckman Coulter GmbH, Bioview, Inc., Clearbridge BioMedics Pte Ltd., Singapore, Cynvenio Biosystems, Exosome Diagnostics, Inc., Fluxion Biosciences, Foundation Medicine, Universitätsklinikum Hamburg-Eppendorf, Brooklyn ImmunoTherapeutics, LLC, Ohio State University, Palo Alto Research Center, Rarecells, Silicon Biosystems, The Scripps Research Institute, University of Minnesota, Janssen Diagnostics, LLC, University of Regensburg, Innocrin Pharmaceuticals Inc.
- Study start
- Apr 1990
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 21 Dec 2007 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The Genitourinary Oncology/Urology Services at Memorial Sloan-Kettering Cancer Center (MSKCC) participates in research for the control, treatment, and cure of cancer. The purpose of this study is to collect normal and cancerous tissues, in addition to blood, and other body fluid samples from men with prostate cancer or prostatic disease. These samples may be stored for future use or used immediately by researchers who study prostate cancer and try to find better ways to diagnose, prevent, and treat it. We will look for genetic changes and protein markers on these cells. We hope to learn more about what makes some people get prostate cancer, why some cancers are more aggressive than others, and why some cancers respond to or resist different treatments. We may also try to grow the tumor cells in the lab. We may find a new treatment for prostate cancer based on this research.
Detailed description
The therapeutics program for advanced prostate cancer is based on the hypothesis that the factors contributing to and associated with progression change as the disease evolves. To categorize these changes we now consider the disease as a series of states. 1 The states represent points where an intervention might be considered to prevent cancer from developing, to eliminate established disease, or to delay progression. The states also represent clinically significant milestones that can be used to assess treatment effects.
Study design
- Observational model
- Case only
- Time perspective
- Other
Who may qualify
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- All patients meeting the eligibility criteria and receiving or seeking prostate cancer treatment in the Genitourinary Oncology/Urology Services will be approached by a consenting professional at a suitable point in their clinical course prior to biospecimen collection.
Key inclusion criteria (7 listed)
- No Cancer Diagnosis
- Clinically Localized Disease
- Rising PSA
- Clinical Metastases: Noncastrate
- Clinical Metastases: Castrate (Testosterone ≤ 50 ng/ml)
Key exclusion criteria (1 listed)
- -Patients without any prostate related problems.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Mar 2026.
- Memorial Sloan Kettering Cancer CenterLink provided by the sponsor.
Related trials for Prostate Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
Active, not recruitingObservational study
MRI Fusion Biopsy vs. Micro-Ultrasound Guided Biopsy
Prostate Cancer
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Recruiting
Rehabilitation and Sex Therapy to Optimize Recovery After Prostate Cancer Treatment
Prostate Cancer, Urinary Incontinence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Susan Slovin, MD principal investigator
Memorial Sloan Kettering Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Prostate Cancer, run by Memorial Sloan Kettering Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 9 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Mar 2026.